Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,221
  • Shares Outstanding, K 17,908
  • Annual Sales, $ 12,690 K
  • Annual Income, $ -29,120 K
  • 60-Month Beta 2.44
  • Price/Sales 18.74
  • Price/Cash Flow N/A
  • Price/Book 3.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/20
See More
  • Average Estimate -0.70
  • Number of Estimates 5
  • High Estimate -0.61
  • Low Estimate -0.78
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -112.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.64 +16.92%
on 08/27/20
14.46 -5.88%
on 09/11/20
+0.31 (+2.33%)
since 08/21/20
3-Month
9.62 +41.48%
on 07/31/20
14.46 -5.88%
on 09/11/20
+0.71 (+5.54%)
since 06/23/20
52-Week
5.61 +142.82%
on 03/18/20
18.96 -28.22%
on 01/21/20
-0.05 (-0.37%)
since 09/23/19

Most Recent Stories

More News
KalVista Pharmaceuticals Reports First Fiscal Quarter Results

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided...

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals Provides Operational and Financial Update

--- Cash Runway Extended into 2022 -

KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided...

KALV : 13.44 (-0.22%)
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

MRK : 83.48 (+0.65%)
UTHR : 102.26 (-0.03%)
CORT : 17.43 (-2.19%)
KALV : 13.44 (-0.22%)
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

UTHR : 102.26 (-0.03%)
PCRX : 59.61 (-1.47%)
NOVN : 0.5332 (-3.05%)
KALV : 13.44 (-0.22%)
KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced...

KALV : 13.44 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade KALV with:

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

2nd Resistance Point 14.42
1st Resistance Point 13.95
Last Price 13.44
1st Support Level 12.84
2nd Support Level 12.20

See More

52-Week High 18.96
Fibonacci 61.8% 13.86
Last Price 13.44
Fibonacci 50% 12.28
Fibonacci 38.2% 10.71
52-Week Low 5.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar